Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week open-label ziprasidone extension study in children and adolescents with bipolar I disorder
2020-004088-26Phase 3
- Sponsor
- Pfizer
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ziprasidone in bipolar I disorder, sponsored by Pfizer. Primary endpoint: Change from baseline in Young Mania Rating Scale.
02
Drugs
ziprasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2020-004088-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004088-26.